HALKUFF DAWN 4
4 · Xeris Biopharma Holdings, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Xeris (XERS) Director Dawn Halkuff Sells Shares, Receives Awards
What Happened
- Dawn Halkuff, a director of Xeris Biopharma (XERS), sold 20,000 shares in an open-market transaction on June 4, 2026 for a weighted average price of $6.09, generating $121,886 in proceeds.
- On the same date she was granted 24,193 restricted stock units (RSUs) (no purchase price) and a derivative grant of 32,996 stock options/awards with a reported price basis of $6.15 (total reported value for the derivative grant ~$202,925). The RSUs and options vest in full upon the earlier of June 4, 2026 or the company’s next annual meeting, subject to continued service.
Key Details
- Transaction date: June 4, 2026; Form 4 filed June 5, 2026 (timely).
- Sale details: 20,000 shares sold, weighted-average price $6.09; sale prices ranged $5.96–$6.17 (report notes multiple trades).
- Grants: 24,193 RSUs (F3) and 32,996 stock option-type awards (F5) were reported as acquired. Vesting is contingent on continued service and the earlier of June 4, 2026 or the next annual meeting.
- Footnotes: Sale executed under a pre-established Rule 10b5-1 trading plan adopted Sept 4, 2025 (F1). Reporting person disclaims beneficial ownership except for pecuniary interest (F4).
- Shares owned after the transactions are not specified in the filing.
Context
- The sale was effected under a 10b5-1 plan (pre-set trading arrangement), which is typically used to sell shares systematically rather than as an ad-hoc indicator of sentiment.
- The reported awards are grants (not exercises) and will vest subject to service conditions; they are not immediate cash or share sales.
Insider Transaction Report
Form 4
HALKUFF DAWN
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-06-04$6.09/sh−20,000$121,886→ 95,000 total - Award
Common Stock
[F3]2026-06-04+24,193→ 119,193 total - Award
Stock Option (Right to Buy)
[F5]2026-06-04$6.15/sh+32,996$202,925→ 32,996 totalExercise: $6.15Exp: 2036-06-04→ Common Stock (32,996 underlying)
Holdings
- 5,410(indirect: By Trust)
Common Stock
[F4]
Footnotes (5)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.960 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
- [F4]The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- [F5]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.
Signature
/s/ Beth Hecht, Attorney-in-Fact|2026-06-05